ISIN | LU1047617987 |
---|---|
Valor Number | 23948713 |
Bloomberg Global ID | |
Fund Name | Crossfund Sicav-Crossinvest Swiss Opportunity Fund A-CHF |
Fund Provider |
Crossinvest SA
Lugano, Switzerland Phone: +41 91 911 88 88 E-Mail: info@crossinvest.ch Web: www.crossinvest.ch |
Fund Provider | Crossinvest SA |
Representative in Switzerland |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(s) |
FundPartner Solutions (Suisse) SA Genève 3 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve a long term capital growth in Swiss Francs by pursuing exposure opportunities to the Swiss market. The Sub-Fund will achieve its objective by taking exposure directly and indirectly in any type of equity and equity related securities of companies which are domiciled, headquartered or exercise the predominant part of their activity in Switzerland. |
Peculiarities |
Current Price * | 173.11 CHF | 31.03.2025 |
---|---|---|
Previous Price * | 176.74 CHF | 28.03.2025 |
52 Week High * | 181.27 CHF | 03.03.2025 |
52 Week Low * | 156.35 CHF | 16.04.2024 |
NAV * | 173.11 CHF | 31.03.2025 |
Issue Price * | 173.11 CHF | 31.03.2025 |
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 44,324,251 | |
Unit/Share Assets *** | 40,605,894 | |
Trading Information SIX |
YTD Performance | +6.81% |
31.12.2024 - 31.03.2025
31.12.2024 31.03.2025 |
---|---|---|
1 month | -3.43% |
28.02.2025 - 31.03.2025
28.02.2025 31.03.2025 |
3 months | +6.81% |
31.12.2024 - 31.03.2025
31.12.2024 31.03.2025 |
6 months | +1.72% |
30.09.2024 - 31.03.2025
30.09.2024 31.03.2025 |
1 year | +7.61% |
02.04.2024 - 31.03.2025
02.04.2024 31.03.2025 |
2 years | +11.96% |
31.03.2023 - 31.03.2025
31.03.2023 31.03.2025 |
3 years | +3.68% |
31.03.2022 - 31.03.2025
31.03.2022 31.03.2025 |
5 years | +29.94% |
31.03.2020 - 31.03.2025
31.03.2020 31.03.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Roche Holding AG | 9.61% | |
---|---|---|
Nestle SA | 9.59% | |
Novartis AG Registered Shares | 9.33% | |
UBS Group AG | 6.14% | |
Zurich Insurance Group AG | 5.05% | |
ABB Ltd | 4.85% | |
Siegfried Holding AG | 4.24% | |
Holcim Ltd | 3.46% | |
Swiss Re AG | 3.45% | |
Givaudan SA | 3.27% | |
Last data update | 30.11.2024 |
TER | |
---|---|
TER date | |
Performance Fee *** | 20.00% |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | |
SRRI ***
|
|
SRRI date *** | 28.02.2025 |